

The logo for the 2nd Global Liver Health Forum is a stylized, orange-to-red gradient shape with a hexagonal pattern. It contains the text "2nd GLOBAL LIVER HEALTH FORUM" in white, bold, sans-serif font.

**2nd GLOBAL
LIVER
HEALTH
FORUM**

SCIENCE TO ADVANCE LIVER HEALTH

Friday, 8th October 2021

Virtual Forum

SANOFI 



SUMMARY



Welcome letter 4

Agenda..... 5

SPEAKER BIOGRAPHIES

Professor Nobert Stefan 6

Professor Marek Hartleb 7

Professor Carmen Fierbinteanu 8

Professor Evgenii Sas 9



WELCOME LETTER

Dear colleague,

It gives us great pleasure to welcome you to the second webinar of the **2nd Global Liver Health Forum!** This meeting follows the success of the first webinar held in June of this year, which connected over 1500 healthcare professionals from 30 countries. The second webinar of the series aims to build on this success by continuing to raise awareness of key factors influencing NAFLD and liver health management, and discuss vital paradigm shifts in this field. The third and final webinar in this series will be held shortly after the second, on the 22nd of October.

During this meeting, we will underline the importance of early diagnosis of NAFLD, diagnostic tools that allow early detection and effective treatments for NAFLD. We will also explore the impact of the metabolic associated fatty liver disease (MAFLD) concept on patient management, disease classification and existing diagnostic and treatment guidelines. Emerging trends in NAFLD/MAFLD and fatty liver management will also be discussed, including the use of essential phospholipids in the treatment of NAFLD/MAFLD and alcoholic liver disease (ALD).

The latest technology ensures the 2nd Global Liver Health Forum will be dynamic, interactive and will allow us to gain insights from participants across the world. This event presents a valuable opportunity to collaborate with and learn from world-renowned scientific experts, who will provide their perspectives on this disease and its management. There will be ample opportunity to engage with the faculty and we encourage you to ask questions throughout the meeting that will be answered by the experts during the Q&A sessions. We hope that you and your peers from all over the world will enjoy this engaging and informative meeting.

We would like to express our sincere gratitude to the people who made this meeting possible. We extend a special thanks to our faculty, who have dedicated their time to sharing their knowledge and passion with us all.

Yours sincerely,

Etienne Pouteau

Global Medical Head for Digestive Health,
Sanofi Consumer Healthcare

Branko Popovic

Global Medical Lead for Digestive Health,
Sanofi Consumer Healthcare

AGENDA

Friday, 8th October 2021

TIME CET (UTC+2)	TOPICS	SPEAKER
10:00–10:10	Welcome and introduction	Sanofi and Professor Marek Hartleb (Chair) (POL)
Session 1		
10:10–10:25	Early diagnostics of NAFLD – spotting warning signs to prevent progression	Professor Norbert Stefan (GER)
10:25–10:40	Healthcare practitioners' diagnostic and treatment practice patterns of NAFLD in Poland – a real-world evidence study	Professor Marek Hartleb (POL)
10:40–10:50	Q&A	
10:50–11:00	Break	
Session 2		
11:00–11:15	The importance of fast identification and understanding disease progression – key notes for NAFLD management	Professor Carmen Fierbinteanu (ROU)
11:15–11:30	Essential phospholipids – efficacy across the spectrum of NAFLD origins	Professor Evgenii Sas (RUS)
11:30–11:40	Q&A	
11:40–11:45	Summary and closing remarks	Sanofi and Professor Marek Hartleb (Chair) (POL)



Professor Norbert Stefan

Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Centre Munich, Germany. University Hospital of Tübingen, Germany.

Professor Stefan is Head of the Department of Pathophysiology of Prediabetes at the Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich. He is also Heisenberg Professor for Clinical and Experimental Diabetology at the University Hospital of Tübingen, Germany.

Professor Stefan has received several national and international scientific awards and was both a member of the executive committee and president of the 2015 congress of the German Diabetes Association. Professor Stefan is presently Associate Editor of the scientific journal *Diabetes* and member of the International Advisory Board of *The Lancet Diabetes & Endocrinology* and received a Visiting Professorship from the Harvard Medical School.

Early diagnostics of NAFLD – spotting warning signs to prevent progression

What will you learn:

- How can early identification of NAFLD improve outcomes for your patients?
- Which diagnostic measures you can use for early detection of NAFLD and how steatosis influences NAFLD diagnosis
- How do diabetologists compensate for the late diagnosis of NAFLD?



Professor Marek Hartleb

Department of Gastroenterology and Hepatology and School of Medicine at the Medical University of Silesia, Katowice, Poland.

Professor Hartleb currently serves as the Head of the Department of Gastroenterology and Hepatology at the Medical University of Silesia in Katowice. He is also the Head of the Scientific Committee of the School of Medicine at the same university.

Since 2014, Professor Hartleb has been the President of the Hepatology Section of the Polish Gastroenterology Society and holds the post of the Vice-President of the Polish Gastroenterology Society. He is the Editor-in-Chief of the national scientific journal *Gastroenterologia praktyczna* (Practical gastroenterology).

Healthcare practitioners' diagnostic and treatment practice patterns of NAFLD in Poland – a real-world evidence study

What will you learn:

- Learnings from the RESTORE study: GP and gastroenterologist experiences
- Can real-world evidence improve the way you manage patients with NAFLD?
- How important is improvement of the quality of life for your patients with NAFLD?
- How understanding experiences of patients with NAFLD can improve your clinical practice





Professor Carmen Fierbinteanu

Internal Medicine and Gastroenterology Department, University Hospital, Bucharest, Romania.

Professor Fierbinteanu serves as Division Chief of the Internal Medicine and Gastroenterology Department at The University Hospital Bucharest. She holds board certifications in Internal Medicine, Gastroenterology, Diagnostic and Interventional Abdominal Ultrasonography and participates as evaluating faculty in the Ministry of Health's Residency Selection and Board Certification Exams.

As a member of The European Association for the Study of the Liver and The American Gastroenterological Association, Professor Fierbinteanu has published numerous abstracts and articles and has delivered posters and oral presentations at international meetings. She has led two national research projects and continues to be Principal Investigator for several international projects.

The importance of fast identification and understanding disease progression – key notes for NAFLD management

What will you learn:

- Can early diagnosis and fast identification of high-risk patients improve clinical outcomes for patients with NAFLD?
- The progression of NASH: key factors in disease management – a multidisciplinary approach
- What can the NAFLD treatment guidelines tell you about optimal management options for patients with NAFLD and choosing hepatoprotective agents?



Professor Evgenii Sas

Saint Petersburg State Pediatric Medical University and S. M. Kirov Military Medical Academy, Russia.

Professor Sas is a Leading Researcher at Saint Petersburg State Pediatric Medical University and a Professor at the S. M. Kirov Military Medical Academy.

Professor Sas is a member of St. Petersburg Society of Physicians, The European Association for the Study of the Liver, The American Association for the Study of Liver Diseases, The Obesity Society and The American Gastroenterological Association. He has authored over 100 research publications on the topics of liver and gastrointestinal diseases.

Essential phospholipids – efficacy across the spectrum of NAFLD origins

What will you learn:

- Could essential phospholipid therapy enhance outcomes in your patients with NAFLD and T2DM or other metabolic comorbidities?
- Should injectable essential phospholipids be prescribed to your patients with NAFLD?
- Can essential phospholipids improve clinical outcomes in patients with ALD?



**2nd GLOBAL
LIVER
HEALTH
FORUM**

SANOFI 

MAT-GLB-2103094
Date of approval: September 2021.